This CDC report provides updated data related to HIV prevalence among people who inject drugs, documenting findings that underscore the need for low-barrier access to comprehensive and integrated needs-based syringe service programs for necessary prevention and
This PowerPoint slide deck reviews the foundations of harm reduction philosophy and practice, summarizes drug user health issues and trends, and aims to increase cultural competence and humility when working with people who use drugs.
In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
There are so many factors that impact adherence and health outcomes. During this Connecting Care podcast, Drs. Alex Walley, Jessica Taylor, and Sim Kimmel discuss HIV prevention and treatment among people who inject drugs.
When people learn there's a pill that's been available for many years, that will keep them safe from HIV. They are surprised and may want to know more. And when people are surprised and even upset, we know we need to do more.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).
